IDH1/2 mutations, one of the most characteristic gene mutations in cholangiocarcinoma, result in elevated levels of (R)-2-hydroxyglutarate (R-2HG), which inhibits the α-ketoglutarate (α-KG)-dependent dioxygenase activity of FTO (Fig. 3). The gene discussed is FTO; the disease is cholangiocarcinoma.